Use of Abciximab for Mediation of Thromboembolic Complications of Endovascular Therapy

We describe four cases in which abciximab was used as a thrombolytic rescue agent in the setting of thrombotic events complicating interventional neuroradiologic procedures. After IV administration of abciximab, the thrombus resolved within 30 min in three cases, whereas no thrombolysis occurred in...

Full description

Saved in:
Bibliographic Details
Published in:American journal of neuroradiology : AJNR 2001-10, Vol.22 (9), p.1764-1767
Main Authors: Cloft, Harry J, Samuels, Owen B, Tong, Frank C, Dion, Jacques E
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal - therapeutic use
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Female
Humans
Immunoglobulin Fab Fragments - therapeutic use
Interventional
Intracranial Embolism - drug therapy
Intracranial Embolism - etiology
Intracranial Thrombosis - drug therapy
Intracranial Thrombosis - etiology
Medical sciences
Neuroradiography - adverse effects
Pharmacology. Drug treatments
Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors
Radiography, Interventional - adverse effects
Thrombolytic Therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We describe four cases in which abciximab was used as a thrombolytic rescue agent in the setting of thrombotic events complicating interventional neuroradiologic procedures. After IV administration of abciximab, the thrombus resolved within 30 min in three cases, whereas no thrombolysis occurred in the fourth case despite the addition of intraarterial tissue plasminogen activator. Further evaluation of glycoprotein IIb-IIIa inhibitors in patients with cerebral thromboembolic events is necessary to prove clinical efficacy.
ISSN:0195-6108
1936-959X